Table 2.
Comparison of AUROC for the performance of simplified criteria to select women eligible for the long-term antiviral treatment at antenatal examination (n = 651).
| HBcrAg Only | HBcrAg + ALT | TREAT-B (HBeAg + ALT) | TA-PROHM | |||||
|---|---|---|---|---|---|---|---|---|
| Cutoff | NA | ≥2 | ≥3 | 4 | ≥2 | ≥3 | 4 | NA |
| AASLD 2018 | ||||||||
| AUROC | 0.71 (0.68–0.75) |
0.90 (0.87–0.92) | 0.88 (0.85–0.90) | 0.76 (0.73–0.80) |
||||
| TP | 40 | 49 | 35 | 10 | 46 | 29 | 3 | 46 |
| FP | 172 | 147 | 18 | 0 | 124 | 8 | 0 | 174 |
| TN | 423 | 448 | 577 | 595 | 471 | 587 | 595 | 421 |
| FN | 16 | 7 | 21 | 46 | 11 | 27 | 53 | 10 |
| Sen | 71.4 | 87.5 | 62.5 | 17.9 | 80.7 | 51.8 | 5.4 | 82.1 |
| (57.8–82.7) | (75.9–94.8) | (48.5–75.1) | (8.9–30.4) | (68.1–90.0) | (38.0–65.3) | (1.1–14.9) | (69.6–91.1) | |
| Spe | 71.1 | 75.3 | 97.0 | 100.0 | 79.2 | 98.7 | 100.0 | 70.8 |
| (67.3–74.7) | (71.6–78.7) | (95.3–98.2) | (99.4–100.0) | (75.7–82.4) | (97.4–99.4) | (99.4–100.0) | (66.9–74.4) | |
| EASL 2017 | ||||||||
| AUROC | 0.76 (0.73–0.80) |
0.76 (0.72–0.79) | 0.72 (0.69–0.76) | 0.71 (0.67–0.74) |
||||
| TP | 60 | 46 | 24 | 9 | 39 | 21 | 3 | 53 |
| FP | 152 | 150 | 29 | 1 | 130 | 16 | 0 | 167 |
| TN | 424 | 426 | 547 | 575 | 446 | 560 | 576 | 409 |
| FN | 15 | 29 | 51 | 66 | 36 | 54 | 72 | 22 |
| Sen | 80.0 | 61.3 | 32.0 | 12.0 | 52.0 | 28.0 | 4.0 | 70.7 |
| (69.2–88.4) | (49.4–72.4) | (21.7–43.8) | (5.6–21.6) | (40.2–63.4) | (18.2–39.6) | (0.8–11.2) | (59.0–80.6) | |
| Spe | 73.6 | 74.0 | 95.0 | 99.8 | 77.4 | 97.2 | 100.0 | 71.0 |
| (69.8–77.2) | (70.2–77.5) | (92.8–96.6) | (99.0–100.0) | (73.8–80.8) | (95.5–98.4) | (99.4–100.0) | (67.1–74.7) | |
Abbreviations: AASLD: American Association for the Study of Liver Disease, ALT: Alanine Aminotransferase, AUROC: Area Under the Receiver Operating Characteristic, EASL: European Association for the Study of the Liver, FN: False Negative, FP: False Positive, Sen: Sensitivity, Spe: Specificity, TDF: Tenofovir Disoproxil Fumarate, TN: True Negative, TP: True Positive, TREAT-B: Treatment Eligibility in Africa for the Hepatitis B Virus.